Gilead CLL drug effective in Phase 2 trial

Gilead Sciences' (GILD) oral spleen tyrosine kinase (Syk) inhibitor GS-9973 demonstrates an overall response (OR) rate of 49% and an estimated progression-free survival (PFS) rate of 70% at 24 weeks in patients with relapsed chronic lymphocytic leukemia (CLL) in a 41-patient Phase 2 clinical trial. 95% of the patients experienced tumor shrinkage and 62% experienced tumor reduction of at least 50%.

Based on these data, the company plans to start new CLL study cohorts to include patients who have relapsed following treatment with other b-cell receptor inhibitors.

From other sites
Comments (2)
  • bberuch
    , contributor
    Comments (314) | Send Message
    Another positive amongst a series of successes. The future looks very good, and if an accelerated status is awarded a larger position seems a viable for my portfolio.
    3 Jun 2014, 11:34 AM Reply Like
  • Kboyd78
    , contributor
    Comments (162) | Send Message
    Is there another large cap growth hitting on more cylinders than GILD, this is a juggernaut
    3 Jun 2014, 12:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs